Integrated health outcomes research strategies in drug or medical device development, pre- and postmarketing: time for change

References

• Rapier CM. An introduction to Health Outcomes Research. Brookwood Medical Publications Ltd, Surrey, UK (1996).
   Google Scholar
• Epstein RS, Sherwood LM. From outcomes research to disease management: a guide for the perplexed. Ann. Intern. Med. 124(9), 832–837 (1996).
   Google Scholar
• Drummond M, Dubois D, Garattini L et al Current trends in the use of Pharmacoeconomics and Outcomes Research in Europe. Value in Health 2(5) 323–332 (1999).
   PubMedGoogle Scholar
• Lasagna L. A plea for the "Naturalistic Study of Medicines". Eur. j Clin. Pharmacol 7, 153–154 (1974).
   PubMedGoogle Scholar
• Downs S, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomized and non-randomized studies of healthcare interventions. J. Epidemiol Commun. Health 52,377–384 (1998).
   PubMed Web of Science ®Google Scholar
• Black N. What observational studies can offer decision makers. Horm. Res. 51 (Suppl. 1), 44–49 (1999).
   Google Scholar
• Black N. Why we need observational studies to evaluate the effectiveness of healthcare. Br. Med.1 312,1215–1218 (1996).
   Google Scholar
• Rothman KJ, Greenland S. Modem epidemiology (second edition). Lippincott-Raven, Philadelphia, USA (1998).
   Google Scholar
• Sacket DL, Richardson WS, Rosenberg W, Haynes RB. Is this evidence about a treatment valid? Is this evidence about a treatment important? Can you apply this valid, important evidence about a treatment in caring for your patient? In: Evidence-based Medicine. How to Practice & Teach EBM Churchill Livingston, New York, USA (1997).
   Google Scholar
• Benson K, Hartz MD. A comparison of observational studies and randomised controlled trials. N Engl. J. Med. 342, 1878–1886 (2000).
   PubMed Web of Science ®Google Scholar
• Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl. J. Med. 342, 1887–1892 (2000).
   Google Scholar
• Ray WA, Griffin MR, Avorn J. Evaluating drugs after their approval for clinical use. N Engl. J. Med. 329,2029–2032 (1993).
   Google Scholar
• Paul JE, Trueman P. Fourth hurdle reviews, NICE and database applications. Pharmacoepidemiol Drug Sal: 10(5), 429–438 (2001).
   PubMedGoogle Scholar
• World Health Organisation. Preamble to the Constitution of the World Health Organization as adopted by the International Health Conference, New York, 19-22 June, 1946; signed on 22 July 1946 by the representatives of 61 States. Official Records of the Work/ Health Organization 2,100 (1946).
   Google Scholar
• Cooke A. Quality of Health and Medical Information on the Internet. Clin. Performance Qua): Healthcare 7(4), 178–182 (1999).
   PubMedGoogle Scholar
• Badia X, Herdman M. The importance of health-related-quality-of-life data in determining the value of drug therapy. Clin. Ther. 23,168–175 (2001).
   PubMedGoogle Scholar
• Sander C, Egger M, Donovan J, Tallon D, Frankel S. Reporting on quality of life in randomised controlled trials: bibliographic studies. Br Med. 317,1191–1194 (1998).
   PubMedGoogle Scholar
• Acquadro C. The European Regulatory Issues on Health-Related Quality of Life Assessment (ERIQA) Project: Preliminary Results and Plans for the Future. Qua): Life Newsletter 24,1–3 (2000).
   Google Scholar
• Santanello NC, Baker D, Cappelleri JC et al. Regulatory issues for health-related quality of life — phrma health outcomes committee workshop, 1999. Value in Health 5(1), 14–25 (2002).
   Google Scholar
• Trueman P, Drummond M, Hutton J. Developing guidance for budget impact analysis. PhannacoEconomks19, 609–621 (2001).
   Google Scholar
• Buxton MJ, Drummond MF, Van Hout BA et al. Modelling in economic evaluation: An unavoidable fact of life. Health Econ. 6, 217–227 (1997).
   PubMed Web of Science ®Google Scholar
• Sculper M, Drummond M, Buxton M. The iterative use of economic evaluation as part of the process of health technology assessment.j Health Serv. Res. Policy 2, 26–30 (1997).
   Google Scholar
• Barendregt JJ, Bonneux L. The trouble with health economics. Eur. J Public Health 9, 309–312 (1999).
   Google Scholar
• Friedberg M, Saffran B, Stinson TJ, Nelson W, Bennett CL. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA 282 (15), 1453–1457 (1999).
   PubMed Web of Science ®Google Scholar
• Drummond ME A reappraisal of economic evaluation of pharmaceuticals. Science or marketing? PharmacoEconomics 14(1), 1–9 (1998).
   Google Scholar
• Task Force on Principles for Economic Analysis of Healthcare Technology. Economic analysis of healthcare technology. Ann. Intern. Med 122, 61–70 (1995).
   Google Scholar
• Guidelines for Economic Evaluation of Pharmaceuticals: Canada. Canadian Office for Health Technology Assessment. 2nd edition (1998).
   Google Scholar
• Drummond R, Luft HS. Pharmacoeconomic analyses: making then transparent, making them credible. JAMA 283(16), 2158–2160 (2000).
   PubMedGoogle Scholar
• Drummond M. The emerging government requirement for economic evaluation of pharmaceuticals. PharmacoEconomics 6\(Suppl. 1), 42–50 (1994).
   Google Scholar
• Drummond MF, Rutten F, Brenna A et al. Economic evaluation of pharmaceuticals: a European perspective. PharmacoEconomics 4(3), 173–186 (1993).
   PubMedGoogle Scholar
• Genduso LA. Review of health economic guidelines in the form of regulations, principles, policies, and positions. Drug Information 30, 1003–1016 (1996).
   Google Scholar
• McDonald R, Haycox A, Walley T. The impact of health economics on healthcare delivery. The health economists perspective. PharmacoEconomics 19(8), 803–809 (2001).
   Google Scholar
• Sacristan JA, Soto J, Galende I, Hylan TR. Randomized database studies: a new method to assess drugs' effectiveness? J Clin. Epidemiol. 51(9), 713–715 (1998).
   Google Scholar
• Lloyd A, Grant D. Incorporating Reimbursement Requirements into the Drug Development Process. Spectrum Reimbursement, Pharmacoeconomics, and Disease Management. 10–1 — 10–12 (June 29 2001).
   Google Scholar
• Garcia Navarro MD, Orozco Beltran D, Gil Guillén V, Carratald Munuera C, Terol Molt6 C, Merino Sanchez J. Relación entre incumplimiento farmacológico y grado de control en pacientes con hipertensi6n, diabetes o dislipemia. Med. Din. 116, 141–146 (2001).
   Google Scholar